In contrast to prior studies focused on DNA alteration status30,31, we have been able to identify a robust association between our gene-expression-based signature and chemotherapy response in early-stage breast cancer by focusing on a transcriptional profile most consistent with TP53 loss of function. This evidence concerns the gene TP53 and breast cancer.